Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | BRS3 | P32247 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1197794 | 1.00 | CYP17A1 (0.47) | CYP17A1NAMPTRAB9AATRBRS3 | |
| SCHEMBL29957148 | 0.89 | CYP17A1 (0.47) | CYP17A1NAMPTRAB9AATRBRS3 | |
| SCHEMBL1020140 | 0.89 | CYP17A1 (0.47) | CYP17A1NAMPTRAB9AATRBRS3 | |
| SCHEMBL14291605 | 0.85 | NAMPT (0.43) | CYP17A1NAMPTRAB9AATRBRS3 | |
| SCHEMBL3543797 | 0.84 | NAMPT (0.42) | CYP17A1NAMPTRAB9AATRBRS3 | |
| SCHEMBL3543792 | 0.84 | NAMPT (0.42) | CYP17A1NAMPTRAB9AATRBRS3 | |
| SCHEMBL18522430 | 0.83 | NAMPT (0.50) | CYP17A1NAMPTRAB9AATRBRS3 | |
| SCHEMBL4066041 | 0.83 | CCNC (0.44) | CYP17A1NAMPTRAB9AATRBRS3 | |
| SCHEMBL30895932 | 0.82 | LATS1 (0.51) | CYP17A1NAMPTRAB9AIDO1 | |
| SCHEMBL27380781 | 0.82 | LATS1 (0.51) | CYP17A1NAMPTRAB9AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | CYP17A1 560/4885NAMPT 3311/4885RAB9A 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.